| Name | Title | Contact Details |
|---|
Aerpio Therapeutics is a Cincinnati, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector. Aerpio Therapeutics is a biopharmaceutical company focused on the development of novel therapeutics for vascular disorders with a concentration on diseases of the eye.
Epicentre Technologies Corp is a Madison, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Groton Biosystems is a Boxborough, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Quva is a national provider specializing in health-system pharmacy services, focusing on sterile injectable compounding and advanced data software platforms. The company operates FDA-registered 503B outsourcing facilities that manufacture ready-to-administer compounded sterile pharmaceuticals, serving thousands of hospitals across the United States. Quva adheres to stringent cGMP standards and utilizes automation and integrated technologies to ensure a reliable supply of high-quality medications. Quvas operations are divided into two main divisions. Quva Pharma delivers essential sterile compounded medications, addressing supply chain reliability and medication shortages. Quva BrightStream offers a data analytics platform that aggregates and analyzes healthcare data, providing actionable insights to optimize pharmacy operations. The company emphasizes patient safety, transparent customer service, and a commitment to innovation and quality, making it a trusted partner for health systems and hospital pharmacies.
NanoCellect`s mission is to facilitate biomedical breakthroughs by making cell analysis and sorting technology more affordable and easier to use. Our microfluidic flow cytometry platforms enable biomedical scientists to analyze and sort cells required for drug discovery, diagnostics, and basic research. The company was founded in late 2009 as a spinout from UCSD and dedicated 6 years developing the foundation of the WOLF`s technology before launching the WOLF (our first product) in 2016. Initial funding of R&D was graciously funded by multiple NIH SBIR grants and contracts and recently backed by FusionX Ventures and other private investors.